On October 12, 2020 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, reported Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa, being held virtually October 12-16, 2020 (Press release, BrainStorm Cell Therapeutics, OCT 12, 2020, View Source;gene-meeting-on-the-mesa-301150038.html [SID1234568358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lindborg’s presentation will be in the form of an on-demand webinar that will be available beginning today. Those who wish to listen to the presentation are required to register here. At the conclusion of the 2020 Cell & Gene Meeting on the Mesa, a copy of the presentation will also be available in the "Investors and Media" section of the BrainStorm website under Events and Presentations.

About the 2020 Cell & Gene Meeting on the Mesa

The conference will feature 80+ on-demand company presentations by leading public and private companies, highlighting their technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, and tissue engineering. Registrants will have access to 15+ expert-led panels and workshops including a mix of both live and on-demand sessions. The conference will be delivered in a virtual format over the course of five days – October 12-16. There is also a premier partnering system, partneringONE, allowing registrants to plan 1×1 meetings with other attendees. For a list of presenting companies, refer to View Source

On October 12, 2020 KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, reported that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020 (Press release, KAHR Medical, OCT 12, 2020, View Source [SID1234568356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The ASH (Free ASH Whitepaper) Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate," said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. "We look forward to advancing the clinical development of this novel therapy."

The following abstract will be posted on the ASH (Free ASH Whitepaper) website on November 5, 2020, at 9:00 a.m. ET:

Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Publication Number: 173
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Session Date: Saturday, December 5, 2020
Session Time: 12:00 PM – 1:30 PM
Presentation Time: 12:30 PM

Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance

About DSP107

DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumor antigen-specific, activated T-cells. CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a "don’t eat me" signal. DSP107 binds CD47 on cancer cells, blocking interaction with SIRPα and thus, blocking the "don’t eat me signal". Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumor destruction.

About DPS107 Phase I/II

A Phase I/II clinical trial to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 as a monotherapy and in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq) in patients with advanced solid tumors is currently being activated. The preliminary efficacy of both DSP107 monotherapy and combination therapy with atezolizumab will also be evaluated in patients with advanced non-small-cell lung carcinoma (NSCLC) who progressed after treatment with PD-1/PD-L1 inhibitors. The study will be conducted at multiple centers in the United States under a clinical collaboration with Roche.

On October 12, 2020 Oxular Limited ("Oxular"), a leading retinal therapeutics development company, reported it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company’s proprietary drug in development for the treatment of retinoblastoma (Press release, Oxular, OCT 12, 2020, View Source [SID1234568355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Retinoblastoma is a rare form of eye cancer that usually develops in early childhood, typically before the age of five. This form of cancer develops in the retina, which is the specialised light-sensitive tissue at the back of the eye that detects light and colour. The most common first sign of retinoblastoma is a visible whiteness in the pupil called "cat’s eye reflex" or leukocoria. Other signs and symptoms of retinoblastoma include crossed eyes or eyes that do not point in the same direction (strabismus), a change in eye colour, redness, soreness, or swelling of the eyelids, and blindness or poor vision in the affected eye or eyes.

Retinoblastoma is often curable when it is diagnosed early. However, if it is not treated promptly, this cancer can spread beyond the eye to other parts of the body. This advanced form of retinoblastoma can be life-threatening.

Current treatment options for retinoblastoma include systemic chemotherapy and intra-arterial chemotherapy, which are very invasive procedures and require specialised facilities and hospital stay. Intra-arterial chemotherapy is only available in select centres. These treatments can lead to significant side effects for patients, including neurocognitive impairment, loss of vision and hearing, and life-threatening infections (sepsis) from low blood counts (neutropenia).

Oxular’s OXU-003 programme for the treatment of retinoblastoma consists of a proprietary anti-tumour drug which utilises Oxular’s formulation and ocular administration technology to safely deliver a precise amount of drug adjacent to the primary ocular tumour (local or targeted chemotherapy). OXU-003 has been shown to be effective as a stand-alone therapy in preclinical models and is complementary with other agents currently used to treat retinoblastoma. Oxular’s minimally invasive local therapeutic approach is intended to be less risky compared to current treatments, is expected to spare patients from related side effects while preserving vision and can be administered by an ophthalmic surgeons in standard operating theatres without the need of specialised equipment.

Mr. Manoj Parulekar, Paediatric Consultant Ophthalmologist, Birmingham Children’s Hospital, commented:

"I am very pleased to see the U.S. FDA’s acknowledgement of the critical and urgent need to develop an effective, safer and easily accessible treatment for Retinoblastoma which is such a devastating disease. Given the potential severe side effects associated with current treatments, which can have life-long impact on children’s lives, it is important that these patients have another treatment available to them."

Thomas Cavanagh, Chief Executive Officer of Oxular commented:

"We are delighted to receive these Rare Paediatric Disease and Orphan Drug designations, which provide important momentum for our OXU-003 development program, as we expect to enter human clinical trials and generate data within the next two years. OXU-003 is a potential breakthrough therapy that utilises Oxular’s core technology to maximise the opportunity for successful treatment while preserving quality of life for these young patients."

The U.S. FDA grants Rare Paediatric and Orphan Drug designations to drugs intended for the treatment of rare diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S. If a future New Drug Application (NDA) for OXU-003 is approved, Oxular is eligible to receive a Priority Review Voucher that may be sold or transferred.

The first NDA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA Orphan Drug designation is entitled to various incentives of the Orphan Drug Act (ODA), including tax credits for qualified clinical testing, waiver of NDA / biologics license application (BLA) user fees, and eligibility for a seven-year exclusive marketing period for that drug and use upon marketing approval.

On October 12, 2020 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, reported that it will present two abstracts relating to its first product, the Nu.Q Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, October 15 through Saturday, October 17 (Press release, VolitionRX, OCT 12, 2020, View Source [SID1234568353]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first abstract "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Lymphoma," will be presented on Friday, October 16 at 1:30 p.m. Eastern Time.

The second abstract, "Characterizing Circulating Nucleosomes in the Plasma of Dogs with Hemangiosarcoma," will be presented on Saturday, October 17 at 11:15 a.m. Eastern Time.

Volition will release further details regarding these abstracts on Friday, October 16.

Volition is proud to sponsor the 2020 VCS Virtual Annual Conference and will be providing more information about the veterinary applications of its Nucleosomics technology for early detection of cancer and other diseases from a virtual exhibition booth at the event.

To register for this conference click here.

The abstracts will be posted to the Volition website on Monday October 19.

On October 12, 2020 CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, reported that it has named the winners of its Third Annual Ovarian Cancer Heroes awards program (Press release, CURE Media Group, OCT 12, 2020, View Source [SID1234568345]). The virtual celebration will be held Friday, Oct. 16, 6-7:30 p.m. CDT, in conjunction with the National Ovarian Cancer Coalition Together in TEAL- No Boundaries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Keynote speaker Joan Lunden, award-winning journalist, bestselling author, patient advocate and breast cancer survivor, will join this year’s annual evening of gratitude and celebration honoring these three extraordinary individuals from across the globe who have gone above and beyond, making a difference in the lives of those affected by ovarian cancer.

The 2020 OC Heroes winners are the following:

Robin Cohen, B.S.N., RN, OCN, is the CEO and co-founder of the Sandy Rollman Ovarian Cancer Foundation in Wynnewood, Pennsylvania. She is a member of the Oncology Nursing Society, the Society of Gynecologic Nurse Oncologists and Cambridge Who’s Who. Cohen has been recognized as one of the 75 Greatest Living Philadelphians and is the 2016 recipient of the Cindy Melancon Spirit Award. She has served on the board of directors of the Ovarian Cancer National Alliance, is currently the vice president of the Board of the Ovarian Cancer Research Alliance and serves on the board of the World Ovarian Cancer Coalition. Cohen works on behalf of women with ovarian cancer every day so that they can live better and longer lives.
Deborah Zajchowski, Ph.D., is the scientific director of the Clearity Foundation in San Diego, California and oversees the foundation’s treatment decision support services and research efforts. She ensures that patients receive information about the most advanced treatment options for ovarian cancer — tailored to their specific tumor and clinical situation — through one-on-one consultations and regularly updated online resources. As a cancer biologist, Zajchowski has been involved in cancer research and drug/target discovery and development for more than 25 years. Zajchowski is a member of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and has published many research articles on cancer genomics, estrogen action and transcriptional control.
Andrea Herzberg is a 24-year survivor of late-stage ovarian cancer. She received her diagnosis at age 39. Born in Brooklyn, Herzberg graduated from the University at Albany (formerly known as State University of New York at Albany) in 1977. As a news reporter, she worked for the Troy, New York, Times Record and United Press International. Her second career was in community policing. As a rookie, she started out as a beat cop in New York City’s Chinatown. After 26 years in the New York City Police Department, she retired in 2011 with the rank of sergeant, supervisor of a detective squad, from the Special Victims Division. Now, as coordinator of SHARE’s cancer support toll-free ovarian helpline, Herzberg recruits and trains volunteers who are both compassionate listeners and passionate about helping callers find information, support and hope. Herzberg feels privileged to know these women who use their own experiences with a life-threatening illness to help others.
"Congratulations to these remarkable heroes who have dedicated their efforts to raising awareness, education and research in ovarian cancer," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of CURE Media Group. "Seeing firsthand the compassionate care the medical staff provided to my mother during her ovarian cancer diagnosis, was incredible and has made a lasting impression. We are so grateful to be joined by Joan Lunden and look forward to honoring each hero with their family, friends and colleagues at the Ovarian Cancer Heroes virtual recognition ceremony."

As the longest running female host ever on early morning television, Lunden was the co-host of Good Morning America for nearly two decades. In 2014, Lunden was diagnosed with triple-negative breast cancer, which required chemotherapy, surgery and radiation. An eternal optimist, Lunden turned her diagnosis into a mission to educate and inspire others about prevention, treatment and survival. Throughout Lunden’s treatment, she blogged about her journey on her website and shared her battle and the transformative effect it has had on her life in her book "Had I Known." She has also sought ways to promote change and has successfully advocated for other survivors on Capitol Hill. As host of the PBS Series, ‘Second Opinion with Joan Lunden’ and the Washington Post Podcast, ‘Caring for Tomorrow’, Lunden continues to advocate for health, wellness, and actively communicates with Americans daily through both her social media and her website, JoanLunden.com.

"We are honored to be part of this event once again, and to recognize the remarkable efforts that are being made in the field of ovarian cancer, especially during these unprecedented times," said Mike Petroutsas, senior vice president of the US Oncology Business Unit at GSK. "At GSK, we share a similar mission of improving the lives of women with ovarian cancer, and are proud to offer resources that educate, empower and support this community. I am truly inspired knowing that with our collective efforts, we can help women and their loved ones find a way forward."